A phase 2 trial of MesoPher, a dendritic cell-based immunotherapy, demonstrated a 64% 2-year recurrence-free survival rate in patients with resected pancreatic cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.